# What the 2026 marmoset study measured

- Article ID: research-007
- Product: ACE-031 (ace-031-425)
- Canonical page: https://heritagebiolabs.com/research-library/articles/007-what-the-2026-marmoset-study-measured
- Product collection: https://heritagebiolabs.com/research-library/products/ace-031
- Product page: https://heritagebiolabs.com/product/ace-031-425
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2016, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Some carry messages that tell cells when to change their activity. ACE-031 is a larger engineered fusion protein. It joins the outer, signal-binding part of human activin receptor type IIB to the Fc region of a human antibody. In a 2026 marmoset study, investigators asked whether intercepting signals such as myostatin and activin A would change how much muscle animals had and how much force that muscle could produce. [1]

The researchers randomly assigned 12 healthy adult marmosets to receive either ACE-031 or a control solution and followed them for 14 weeks. The groups included equal numbers of males and females within each group. Body composition was tracked during the experiment, then muscles were sampled for microscopy and mechanical testing. Lean body mass rose from baseline in the treated group. In the upper-arm muscle sampled at the end, both slow and fast fibers were larger on average than those in controls. The relative share of slow fibers was similar across the two groups. [1]

The force results warrant a careful reading. The team removed a lower-leg muscle and stimulated it in a testing chamber. Specific force, which accounts for muscle size, was higher in treated animals in both single-twitch and sustained-contraction tests. The raw force measurements in those comparisons fell short of statistical significance. The experiment could therefore identify changes in the performance of muscle tissue under controlled conditions. It could not measure walking, fatigue during activity, or performance of a task that requires muscles, nerves and joints to work together. [1]

The authors chose a nonhuman primate partly because the balance of muscle growth regulators differs between rodents and primates. A signal that contributes heavily to growth control in mice may contribute a different share in humans. The marmosets help test whether the biological response extends beyond rodents. The animals were healthy, however, and only four received the control solution. A small study with an isolated muscle endpoint provides limited information about the effects of the same molecule in people with muscle disease. [1]

The older human ACE-031 trial in ambulatory boys with Duchenne muscular dystrophy asked a different question and ended early over potential safety concerns, including nosebleeds and small visibly widened blood vessels. Its walking results remained inconclusive. Taken together, the papers give researchers a reason to examine how different growth signals affect primate muscle and a reason to keep clinical safety and day-to-day movement separate from force produced in a lab. [1] [2]

## Sources

1. Samuel M. Cadena et al. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). PLOS ONE (publication 2026-02-13). <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0342666>
2. Craig Campbell et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve (publication 2016-12-23). <https://pubmed.ncbi.nlm.nih.gov/27462804/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 002 - A4 Amyloid Beta and ACE-031.docx; article 7; content SHA-256 fc73e67b58dc6f1890598a5e772edd6f2d8a695591198573fbfc6213c91aff9e.
